ArticleFrontiers in molecular biosciences2025
Identification and validation of mitochondrial-related genes in intestinal ischemia-reperfusion injury based on WGCNA and machine learning.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe ischemia-reperfusion (II/R) injury of the intestines is a leading cause of death and disability. According to earlier research, modulating mitochondrial function is the primary mechanism by which II/R injury is ameliorated. In order to further molecular diagnostics and discover possible treatment targets, it is essential to find biomarkers of mitochondria in II/R injury. Methods: The datasets GSE96733 and GSE37013, along with mitochondrial-related genes (MRGs), were obtained from the Gene Expression Omnibus (GEO) database and MitoCarta3.0, respectively. GSE96733 conducted differential expression gene (DEGs) analysis and weighted gene co-expression network analysis (WGCNA) module screening. In order to find MRGs that were expressed differently, we got their intersection (DEMRGs) and gene enrichment analysis was carried out. The hub genes were screened using machine learning approaches, protein-protein interaction (PPI) network analysis, and Molecular Complex Detection (MCODE). A nomogram was developed for diagnostic evaluation. Furthermore, the relationship between hub gene expression profiles and immune infiltration landscapes was interrogated through immune cell infiltration analysis. The expression patterns of the hub genes were further validated in the II/R injury model through dataset validation and qRT-PCR assays. The procedure concluded in a gene-related hub network, DSigDB prediction of prospective therapeutic compounds, and molecular docking simulations of the drugs' binding affinity with important target proteins. Results: Hub genes have been found in five different DEMRGs: Pdk4, Yrdc, Bcl2l11, Bcl2a1d and Pmaip1. The nomogram model was beneficial for diagnosis. Dendritic cells (DC) and M2 macrophages are strongly linked to the 5 Hub genes, according to immune cell infiltration research. Afterwards, the regulatory network showed that hub genes and miRNAs had a complicated connection. Additionally, securinine and ABT-737 were anticipated to be possible therapeutic agents for II/R injury. The validation results for the four hub genes (Pdk4, Yrdc, Bcl2l11, and Pmaip1), obtained from both independent datasets and qRT-PCR, were consistent with the initial bioinformatics analysis. Conclusion: Pdk4, Yrdc, Bcl2l11, and Pmaip1 have been identified as hub genes closely associated with mitochondrial function in eraly II/R injury, thereby providing a theoretical basis for the diagnosis and treatment of eraly II/R injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.